INSMED Inc. Files Current Report on Form 8-K

Ticker: INSM · Form: 8-K · Filed: 2024-05-09T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financial-reporting, company-update

TL;DR

INSMED filed an 8-K on May 9th, updating on financials and corporate events.

AI Summary

On May 9, 2024, INSMED Inc. filed an 8-K report detailing its financial results and other events. The company, incorporated in Virginia with its principal executive offices in Bridgewater, New Jersey, operates in the pharmaceutical preparations sector. This filing serves as a current report under the Securities Exchange Act of 1934.

Why It Matters

This filing provides investors and the public with timely updates on INSMED Inc.'s financial condition and significant corporate events, crucial for informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine filing of a current report, not indicating any specific new risks or material adverse events.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this Form 8-K filing?

The Form 8-K is a Current Report filed by INSMED Inc. pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting significant corporate events and financial information.

When was this report filed?

This report was filed on May 9, 2024.

Where are INSMED Inc.'s principal executive offices located?

INSMED Inc.'s principal executive offices are located at 700 US Highway 202/206, Bridgewater, New Jersey 08807.

In which state was INSMED Inc. incorporated?

INSMED Inc. was incorporated in Virginia.

What is the Standard Industrial Classification (SIC) code for INSMED Inc.?

The SIC code for INSMED Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-09 07:05:02

Key Financial Figures

Filing Documents

02 – Results of Operations and Financial Condition

ITEM 2.02 – Results of Operations and Financial Condition. On May 9, 2024, Insmed Incorporated (the "Company") issued a press release regarding its financial results for the three months ended March 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 — Other Events

ITEM 8.01 — Other Events. On May 9, 2024, the Company reported topline safety and tolerability data from its Phase 2 study of treprostinil palmitil inhalation powder ("TPIP") in patients with pulmonary hypertension associated with interstitial lung disease and provided an update on blinded data from its ongoing Phase 2 study of TPIP in pulmonary arterial hypertension . A copy of a slide presentation regarding the data is attached hereto as Exhibit 99.2 and incorporated herein by reference.

01 – Financial Statements and Exhibits

ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on May 9, 2024. 99.2 Insmed Incorporated May 9, 2024 Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 9, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing